Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq:NBIX) reported two-year Phase 3 CAHtalyst Pediatric data for CRENESSITY (crinecerfont) in children with classic congenital adrenal hyperplasia at ENDO 2026. Among patients with advanced bone age, mean bone age SDS fell 1.12 and a subset showed a 4.7 cm gain in predicted adult height. A U.S. caregiver survey (n=29) found 100% overall satisfaction, willingness to recommend treatment, and greater optimism about long-term outcomes. CRENESSITY was generally well tolerated through two years, with no new safety signals and sustained glucocorticoid reductions linked to improved insulin resistance, weight and BMI.
Neurocrine Biosciences (NASDAQ:NBIX) reported new two-year Phase 3 CAHtalyst Adult data on CRENESSITY (crinecerfont) in classic congenital adrenal hyperplasia at ENDO 2026.
Adults on CRENESSITY showed sustained glucocorticoid dose reductions (mean -38%), improved weight, BMI, insulin resistance, favorable bone trends, high treatment satisfaction, and no new safety signals.
Neurocrine Biosciences (Nasdaq: NBIX) reported new 48-week KINECT 4 post-hoc data on INGREZZA (valbenazine) for tardive dyskinesia. About 94% of patients achieved either symptomatic remission or a ≥30% AIMS score reduction.
A separate Medicare claims study of 176,000+ TD patients found 90% had hepatic risk factors; INGREZZA is the only VMAT2 inhibitor with approved dosing in hepatic impairment.
Neurocrine Biosciences (Nasdaq: NBIX) reported clinician-reported data on INGREZZA (valbenazine) in 30 individuals with tardive dyskinesia and intellectual and developmental disabilities.
Nearly all showed reduced TD severity; 89% improved within four weeks, with broad gains in functional, physical, and socio-emotional outcomes, including independence, emotions, socializing, dexterity, and speech.
Neurocrine Biosciences (Nasdaq: NBIX) will present multiple new two-year CRENESSITY® (crinecerfont) analyses at ENDO 2026 from June 13‑16 in Chicago.
Presentations cover adult and pediatric classic congenital adrenal hyperplasia, including androgen control, glucocorticoid dose reduction, metabolic and bone outcomes, growth, and quality of life, plus additional VYKAT™ XR data in Prader‑Willi syndrome.
Neurocrine Biosciences (Nasdaq: NBIX) will participate in two June investor conferences, featuring executive fireside chats and webcast access for investors.
The company develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders, with several FDA-approved therapies and multiple mid- to late-stage clinical programs.
Neurocrine Biosciences (Nasdaq: NBIX) reported real-world clinician survey data on mild tardive dyskinesia (TD) and INGREZZA capsules at the APA 2026 meeting. In a subgroup of 90 patients with mild TD, 90% had functional impairment. After starting INGREZZA, 96% showed improved uncontrolled movements, with 86% improving within four weeks. Clinicians also reported high rates of better functional status, independence, daily activities and work or school participation.
Neurocrine Biosciences (Nasdaq: NBIX) completed its acquisition of Soleno Therapeutics, expanding its rare disease portfolio with VYKAT XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome.
The all-cash deal values Soleno at $2.9 billion, with shareholders receiving $53.00 per share. A tender offer closed on May 15, 2026, with 46,356,114 shares (about 88.9%) tendered. A follow-on merger on May 18, 2026, made Soleno a wholly owned subsidiary of Neurocrine, and Soleno’s stock will cease trading on Nasdaq.
Neurocrine Biosciences (Nasdaq: NBIX) announced publication of the first peer-reviewed, expert-driven algorithms to guide glucocorticoid (GC) dose reduction after initiating CRENESSITY® (crinecerfont) for classic congenital adrenal hyperplasia (CAH) in pediatric (4–17 years) and adult patients.
The guidance targets pediatric GC dosing to the upper physiologic range (8–11 mg/m2/day hydrocortisone equivalents) and adult physiologic ranges (2–14 mg/m2/day), and emphasizes gradual, supervised reductions with biomarker and clinical monitoring.
Neurocrine Biosciences (Nasdaq: NBIX) reported first-quarter 2026 results with $811.0M total net product sales, up 44% YoY. INGREZZA sales were $656.9M (+20% YoY); CRENESSITY sales were $153.3M. GAAP net income was $197.9M ($1.91 diluted EPS). The company announced a definitive agreement to acquire Soleno Therapeutics for $2.9B, expected to close in Q2 2026, and reaffirmed 2026 INGREZZA sales guidance of $2.7–$2.8B.